
IRISH JOURNAL OF PSYCHOLOGICAL WOL 17 NO 2 JUN 2000 MEDICINE TISS N 0790-9667

'Oak (detail)' by Tom Molloy 1998-99 (pencil on paper, 25 x 32cm) From the Collection at the Irish Museum of Modern Art, Royal Hospital Kilmainham, Dublin 8.

A brighter outlook for prescribers of fluoxetine



The original brand? - 25% more expensive. Is it time to change?



A more affordable therapy in the treatment of depression



1 GERARD LABORATORIES GEROZAC: (fluoxetine HCL) Abbreviated prescribing information: Presentation: Each capsule contains fluoxetine hydrochloride equivalent to 20 mg of fluoxetine. Indication geroZAC is indicated for the treatment of major depressive episodes. Dose: A dose of 20 mg/day is recommended and a maximum daily dose should not exceed 80 mg/day which can be administered as single or divided dose, during or between meals. Patients with renal or liver disease: In cases of liver dysfunction or renal failure (GFR 10-8 ml/min), the dose should be reduced, e.g. to 20 mg every second day. Children: Fluoxetine capsules are not indicated for use in children and adolescents below the age of 18

Elderly: Caution is recommended when increasing the dose, which should rarely exceed 40 mg and should not exceed 60 mg. Method of administration: For oral administration. Contraindications: Concurrent treatment with MAOIs (monoamine oxidase inhibitors). Cautionary use with other antidepressants. Not to be used where there is severe renal failure (GFR < 10ml/min). Unstable or uncontrolled epilepsy. Not to be used by nursing mothers Hypersensitivity to any of the Ingredients. Precautions: As with all antidepressants risk of suicide particularly at the beginning of treatment due to the delay between treatment and clinical improvement. Concomittant used tryptophan. Epilepsy, electroconvulsive therapy, cardiovascular disease, recent myocardial infarction, diabetes, alcohol, hepatic and renal insufficiency, and overdose. Side-effects: rash and alivering results and mood shift towards manic phase, serotonin syndrome, inappropriate secretion of antidiuretic hormone, anorexia, weight loss, appetite loss, nausea, vomiting, diarrhoea, dry mouth, dyspepsia, constipation, headach, restlessness, insomnia, anxiety, dizziness, visual disturbance, drowsiness, confusion, tremor, sweating, sedation. Small increases in diastolic blood pressure and tachycardia as well as bradycardia. Hyperprotactinemia with galactorines, hyperparation places, protection in properties of the protection of last reviews. December 1999. For full prescribing information please see the Summary of Product Characteristics. Further information is available from: Gerard Laboratories, 2004A Orchard Avenue, CityWest Business Campus, Naas Rd, Dublin 24. FREEPHONE 1809 272 272. Fax: 01 4661912 Reference: 1. MIMS December 1999.

Editor-in Chief: Brian Lawfor Editorial Co-ordinator: Anne Henrichsen

Advertising Manager: Niamh

Founding Editor: Mark Hartman Editors: Timothy Dinan (London) David King (Belfast)

_ _ _ _

Deputy Editor: Brian O'Shea (Dublin)

Associate Editors: Ken Brown (Belfast), Patricia Casey (Dublin)
Anthony Clare (Dublin) Stephen
Cooper (Belfast), Thomas Fahy
(Calway) Michael Fitzgerald (Dublin),
Brian teonard (Galway), Roy
McCfelland (Belfast) Aidan McGennis
(Dublin), Ciaran O Boyle (Dublin),
Eadbhard O Callaghan (Dublin) Art
OfConnor (Dublin) Ethna O Corman
(Belfast), Ign Pullen (Edinburgh), David
Steehan (Tampa), Philip Shaith (Leeds)
Hugh Stauhton (Dublin) John
Waddington (Dublin), Richard Williams
(Vistoria)

Statistical Editors
Rodan Conroy (Dublin)

Submissions & correspondence to:

The Editor, Irish Journal of Psychological Medicine 25 Adelaide Greet Dun taughtine Ca Dublin.

Telephone

01-2803967 Int +353-1-2803967

Fax

01-2807076, ln +353 1 2807076

Pubhsher MedMedia Ltd Media House; 25 Adelaide Street

Dun Laoghaire, Co Dublin

Printing: New Cityview Press

Subscriptions

Rates per valume of faur issues (Mar, Jun Sept, Dec) sta£43 EU Us\$96 USA₇ sta£53 elsewhere (single issues Us\$28 USA sta£1.3 25 elsewhere) incl. airmail postage internationally.

Subscription enquiries, ordersand cheques made payable to: Royal Society of Medicine Press Ltd

1 Wimpole St

fondon W1M 8AE UK.
Tel: 0171 2902927
int: +44-171-2902927
Fax: 0171-2902929
int: +44-171-2902929

Circulation

3,000 to 54 countries.
The Journal participates in the World
Health Organisation project to improve
distribution of scientific materials on
mental health.

Publication does not imply endorsement. Limited photocopying authorisation granted for a fee to Copyright Cléarance Center 27 Congress Street, Salem, MA 01970. USA, or to appropriate Reproduction Rights Organisation; isolated non profit academic photocopying excepted

IRISH JOURNAL OF **PSYCHOLOGICAL MEDICINE**

VOL 17 NO 2 JUNE 2000 ISSN 0790 9667

EDITORIAL

41 Is neuroticism a modifiable risk factor for depression?
Niall Gormley

ORIGINAL PAPERS

- 43 The pattern of support networks among the community dwelling elderly in urban Ireland: variations with mental disorder

 Michael Kirby, Aisling Denihan, Irene Bruce, Davis Coakley, Brian A Lawlor
- Attitudes to doctors and medicine: a failure to replicate
 Ronan Conroy, Ruwani Siriwardena, Olive Smyth, Hannah M McGee Paula Fernandes
- 54 Tecnagers in adult psychiatric inpatient care in Northern Ireland Sinéad McGilloway, Michael Donnelly, David Scott

BRIEF REPORT

59 Suicide rates in Irish counties
John F Connelly David Lester

REVIEW

62 Good practice in ADHD
Eiona McNicholas

HISTORICAL

67 Doctor Maurice O Connor Drury, Wittgenstein's pupil John Wallace

CASE REPORTS

69 A case of co-existant Capgras and deClerambault's syndrome with a history of morbid jealousy

Noel Kennedy, Brendan Kelly David Shantey, Michael Gill

- 71 Sleep paralysis and attempted suicide: a case report Gary Hosty, Joanna Abbott
- 46a John Dunne Medal
- 58 Guidelines for authors
- 73 Letters to the Editor
- 78 Book Reviews

Indexed and abstracted by BIOLOGICAL ABSTRACTS (BIOSIS Previews); CENTRE NATIONAL DE LA RECHERCHE, SCIENTIFICUE/INIST: PASCAL; EXCERPTA MEDICA/EMBASE; INSTITUTE FOR SCIENTIFIC INFORMATION: CURRENT CONTENTS/Social & Behavioural Sciences (Social Science CITATION INDEX, Research Alert); PSYCHOLOGICAL ABSTRACTS (PsycINFO/PsycIIT); Cumulative Index to Nursing & Allied Health Literature, Current AlDS Literature (CAB Abstracts), International Pharmaceutical Abstracts, Linguistics & Language Behaviour Abstracts, Nutrition Abstracts and Reviews, (CAB Abstracts), Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, Sociological Abstracts.

Microfilm, microfiche & article copies from University Microfilms International, 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the Adonis service, whereby article copies can be printed out from compact disks (CD-ROM) on demand; explanatory leaflet available from ADONIS BV, PO Box 639, 1000 AV Amsterdam, The Netherlands. Journal listed in Utrich's International Periodicals Directory (Bowker International Serials Database), EBSCO's Selected Periodicals for the Medical and Health Sciences, & EBSCO's Librarians' Handbook.



Fast Response Can start to improve symptoms of Depression within 7 days 1



A first choice antidepressant



Abbreviated Prescribing Information: LUSTRAL™ (sertraline)

Presentation: Tablets containing 50mg or 100mg sertraline. Indications: Treatment of symptoms of depressive illness, including accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes, including accompanying symptoms of anxiety. Obsessive compulsive disorder (OCD). Panic disorder with or without agreeable in a property of the content of the co

of relapse or recurrence of depressive episodes, including accompanying symptoms of anxiety. Obsessive compulsive disorder (OCD). Panic disorder, with or without agoraphobia.

Dosage: Lustral should be given as a single daily dose. The initial dose in depression and OCD is 50mg and the usual antidepressant dose is 50mg. The initial dose in panic disorder is 25mg, increasing to 50mg after one week. Dosage can be further increased, if appropriate, to a maximum of 200mg daily. Patients should be maintained on the lowest effective dose. Use in children: Not recommended. Use in the elderly: Usual adult dose. Contraindications: Hypersensitivity to this group of drugs. Hepatic insufficiency, unstable epilepsy and convulsant disorders, pregnancy and lactation. Do not use with, or within two weeks of ending treatment with, MAOIs. At least 14 days should elapse before

starting any MAOI following discontinuation of Lustral. **Precautions, warnings**: Renal insufficiency, ECT, epilepsy, driving. Lustral should be discontinued in a patient who develops seizures. Lustral should not be administered with benzodiazepines or other tranquillizers in patients who drive or operate machinery. Serotonergic drugs such as tryptophan or fenfluramine should be used with caution. The patient should be monitored for signs of suicide or mania. **Drug Interactions**: Caution with other centrally active medication. Lithium levels should be monitored. Although Lustral has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. The potential for Lustral to interact with other highly protein bound drugs should be borne in mind. Interactions with e.g. warfarin, diazepam, tolbutamide and cimetidine have not been fully assessed. With warfarin prothrombin time should be monitored when Lustral is initiated or stopped. **Side-Effects**: Dry mouth, nausea, diarrhoea/loose stools, ejaculatory delay, tremor, increased sweating, dizziness, insomnia, somnolence, headache, anorexia and dyspepsia. Rarely, abnormal LFTs, hyponatraemia. The following have been reported with Lustral but may have no causal relationship: vomiting, abdominal pain, movement disorders,

convulsions, menstrual irregularities, hyperprolactinaemia, galactorrhoea, rash and alopecia. Rarely, pancreatitis, serious liver events, altered platelet function, abnormal bleeding and purpura. As with other serotonin re-uptake inhibitors rare reports of agitation, confusion, depersonalisation, hallucinations, nervousness, postural hypotension, hypo/hypertension, tachycardia and arrhythmias. Withdrawal reactions have been reported with Lustral. Common symptoms include dizziness, paraesthesia, headache, anxiety and nausea. Abrupt discontinuation of treatment with Lustral should be avoided. The majority of symptoms experienced on withdrawal of Lustral are non-serious and self-limiting. Legal Category: S1A. Package Quantities: 50mg tablet (PA 822/1/4) Calendar pack of 28, 100mg tablet (PA 822/1/5) Calendar pack of 28. Product Authorisation Holder. Pfizer (Ireland) Limited, Parkway House, Ballymount Road Lower, Dublin 12, Republic of Ireland. Further information on request: Pfizer (Ireland) Limited. Date last revised: June 1999. Reference: 1. Lapierre YD. Int Clin Psychopharmacol 1991; 6 (Suppl. 2): 23-35.

67577 November 99

